Scalability remains the biggest hurdle standing between cell and gene therapy and the patients who need it.

Our CBO Alexa Crăciunescu joined The Medicine Maker’s IBTV Roving Reporter at Alliance for Regenerative Medicine’s Meeting on the Med 2026 in Rome to share her perspective on how automation, digitization, and new manufacturing models can make CGT production more repeatable, efficient, and accessible at scale.

🎥 From closed systems and real-time analytics to AI-enabled automation, watch Alexa alongside other key industry leaders explore what it will take to solve autologous manufacturing’s toughest constraints, here.